Carnitine supplementation for inborn errors of metabolism

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 2, 2012, Pages

  Nasser, Mona ^a   Javaheri, Hoda ^b   Fedorowicz, Zbys ^c   Noorani, Zaman ^d  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b ANIMAL SCIENCE RESEARCH INSTITUTE   (Iran)

^c Bahrain Branch ^*  (Bahrain)

^d Ciris Clinic   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; PLACEBO; VITAMIN B COMPLEX;

CLINICAL OUTCOME; CLINICAL PRACTICE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; INBORN ERROR OF STEROID METABOLISM; MEDICAL DECISION MAKING; PATIENT MONITORING; PERSONAL EXPERIENCE; PHENYLKETONURIA; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; INBORN ERROR OF METABOLISM; INFANT;

CARNITINE; DIETARY SUPPLEMENTS; HUMANS; INFANT; METABOLISM, INBORN ERRORS; VITAMIN B COMPLEX;

EID: 84861312447     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006659.pub3     Document Type: Review

References (55)

1. Angelini C, Trevisan C, Isaya G, Pegolo G, Vergani L. Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency. Clinical Biochemistry 1987;29(1):1-7.
2. Baric I, Zschocke J, Christensen E, Duran M, Goodman SI, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I. Journal of Inherited Metabolic Disease 1998;21(4):326-40.
3. Bhuiyan AK, Jackson S, Turnbull DM, Aynsley-Green A, Leonard JV, Bartlett K. The measurement of carnitine and acyl-carnitines: application to the investigation of patients with suspected inherited disorders of mitochondrial fatty acid oxidation. Clinica Chimica Acta 1992;207(3):185-204.
4. Bjugstad KB, Goodman SI, Freed CR. Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric acidemia type 1. Journal of Pediatrics 2000;137(5):681-6.
5. Bohles H, Ullrich K, Endres W, Behbehani AW, Wendel U. Inadequate iron availability as a possible cause of low serum carnitine concentrations in patients with phenylketonuria. European Journal of Pediatrics 1991;150(6):425-8.
6. Bowyer BA, Fleming CR, Haymond MW, Miles JM. L-carnitine: effect of intravenous administration on fuel homeostasis in normal subjects and home-parenteral-nutrition patients with low plasma carnitine concentrations. American Journal of Clinical Nutrition 1989;49(4):618-23.
7. Chazot C, Blanc C, Hurot J M, Charra B, Jean G, Laurent G. Nutritional effects of carnitine supplementation in hemodialysis patients. Clinical Nephrology 2006;59(1):24-30.
8. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Annals of the New York Academy of Sciences 2004;1033:168-76.
9. Ellaway CJ, Peat J, Williams K, Leonard H, Christodoulou J. Rett syndrome: randomized controlled trial of L-carnitine. Journal of Child Neurology 1999;14(3):162-7.
10. Gillingham MB, Connor WE, Matern D, Rinaldo P, Burlingame T, Meeuws K, et al. Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Molecular Genetics & Metabolism 2003;79(2):114-23.
11. Goa KL, Brogden RN. l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 1987;34(1):1-24.
12. Huidekoper HH, Schneider J, Westphal T, Vaz FM, Duran M, Wijburg FA. Prolonged moderate-intensity exercise without and with L-carnitine supplementation in patients with MCAD deficiency. Journal of Inherited Metabolic Disease 2006;29(5):631-6.
13. Igarashi N, Sato T, Kyouya S. Secondary carnitine deficiency in handicapped patients receiving valproic acid and/or elemental diet. Acta Paediatrica Japonica 1990;32(2):139-45.
14. Kelley RI. The role of carnitine supplementation in valproic acid therapy. Pediatrics 1994;93(6):1174-5.
15. Kolker S, Burgard P, Okun JG, Schulze-Bergkamen A, Assmann B, Greenberg CR, et al. Looking forward-an evidence-based approach to glutaryl-CoA dehydrogenase deficiency. Journal of Inherited Metabolic Disease 2004;27(6):921-6.
16. Krähenbühl S. [Carnitine: vitamin or doping?]. Therapeutische Umschau 1995;52(10):687-92.
17. Lee PJ, Harrison EL, Jones MG, Jones S, Leonard JV, Chalmers RA. L-carnitine and exercise tolerance in medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency: a pilot study. Journal of Inherited Metabolic Disease 2005;28(2):141-52.
18. Maebashi M, Kawamura N, Sato M, Imamura A, Yoshinaga K. Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia. Lancet 1978;2(8094):805-7.
19. Mayer G, Graf H, Legenstein E, Linhart L, Auer B, Lohninger A. L-carnitine substitution in patients on chronic hemodialysis. Nephron 1989;52(4):295-9.
20. Morris AA, Turnbull DM. Fatty acid oxidation defects in muscle [abstract]. Current Opinion in Neurology 1998;11(5):485-90.
21. Muller E, Kolker S. Reduction of lysine intake while avoiding malnutrition--major goals and major problems in dietary treatment of glutaryl-CoA dehydrogenase deficiency. Journal of Inherited Metabolic Disease 2004;27(6):903-10.
22. Schmidt-Sommerfeld E, Penn D, Wolf H. Carnitine deficiency in premature infants receiving total parenteral nutrition: effect of L-carnitine supplementation. Journal of Pediatrics 1983;102(6):931-5.
23. Schulpis KH, Nounopoulos C, Scarpalezou A, Bouloukos A, Missiou-Tsagarakis S. Serum carnitine level in phenylketonuric children under dietary control in Greece. Acta Paediatrica Scandinavica 1990;79(10):930-4.
24. Sirtori CR, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A, Baldassarre D, et al. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutrition, metabolism, and cardiovascular diseases: NMCD 2000;10(5):247-51.
25. Vilaseca MA, Briones P, Ferrer I, Campistol J, Riverola A, Castillo P, et al. Controlled diet in phenylketonuria may cause serum carnitine deficiency. Journal of Inherited Metabolic Disease 1993;16(1):101-4.
26. Winter SC. Treatment of carnitine deficiency. Journal of Inherited Metabolic Disease 2003;26(2-3):171-80.
27. WolffJA, Carroll JE, Le Phuc Thuy, Prodanos C, Haas R, Nyhan WL. Carnitine reduces fasting ketogenesis in patients with disorders of propionate metabolism. Lancet 1986;1(8476):289-91. [MEDLINE: PUBMED 2868163]
28. Yeh YY, Cooke RJ, Zee P. Impairment of lipid emulsion metabolism associated with carnitine insufficiency in premature infants. Journal of Pediatric Gastroenterology & Nutrition 1985;4(5):795-8.
29. Zilleruelo G, Novak M, Hsia SL, Goldberg R, Abitbol C, Monkus E, et al. Effect of dialysate composition on the lipid response to L-carnitine supplementation. Kidney International - Supplement 1989;27:S259-63.
30. Rodriguez DRE, Mendible A, Gomez N, Williams P, Meneses P, Mathison Y. Drug intervention program in dyslipemic children: Use of L-carnitine. Revista Latina De Cardiologia - Euroamericana 1997;18(2):25-30.
31. Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al. How to formulate research recommendations. BMJ 2006;333(7572):804-6.
32. Cairns PA, Stalker DJ. Carnitine supplementation of parenterally fed neonates. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD000950]
33. Chakrapani A, Cleary MA, Wraith JE. Detection of inborn errors of metabolism in the newborn. Archives of Disease in Childhood. Fetal and Neonatal Edition 2001;84(3):F205-10.
34. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
35. Elbourne D, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
36. Evangeliou A, Vlassopoulos D. Carnitine metabolism and deficit--when supplementation is necessary?. Current Pharmaceutical Biotechnology 2003;4(3):211-9.
37. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
38. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
39. Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
40. Itoh T, Ito T, Ohba S, Sugiyama N, Mizuguchi K, Yamaguchi S, et al. Effect of carnitine administration on glycine metabolism in patients with isovaleric acidemia: significance of acetylcarnitine determination to estimate the proper carnitine dose. Tohoku Journal of Experimental Medicine 1996;179(2):101-9.
41. Kölker S, Garbade SF, Greenberg CR, Leonard JV, Saudubray JM, Ribes A, et al. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatric Research 2006;59(6):840-7.
42. Kolker S, Christensen E, Leonard JV, Greenberg CR, Burlina AB, Burlina AP, et al. Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). Journal of Inherited Metabolic Disorders 2007;30(1):5-22.
43. Kruer MC, Steiner RD. The role of evidence-based medicine and clinical trials in rare genetic disorders. Clinical Genetics 2008;74(3):197-207.
44. Leonard JV, Morris AA. Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta Paediatrica 2006;95(1):6-14.
45. Lepage N, Li D, Kavsak PA, Bamforth F, Callahan J, Dooley K, et al. Incomplete pediatric reference intervals for the management of patients with inborn errors of metabolism. Clinical Biochemistry 2006;39(6):595-9.
46. Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technology Assessment 1997;1(7):1-202.
47. Poustie VJ, Wildgoose J. Dietary interventions for phenylketonuria. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD001304.pub2]
48. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
49. Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technology Assessment 1997;1(11):1-95.
50. Steiner RD. Evidence based medicine in inborn errors of metabolism: is there any and how to find it. American Journal of Medical Genetics 2005;134A(2):192-7.
51. Walter JH. L-Carnitine in inborn errors of metabolism: What is the evidence?. Journal of Inherited Metabolic Disease 2003;26(2-3):181-8.
52. Webster D, Wildgoose J. Tyrosine supplementation for phenylketonuria. Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD001507.pub2]
53. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. New England Journal of Medicine 2003;348(23):2304-12.
54. Winter SC, Buist NRM. Inborn errors of Metabolism: Medical and Administrative "Orphans". American Journal of Managed Care 1998;4(8):1164-8.
55. Yi SHL, Singh RH. Protein substitute for children and adults with phenylketonuria. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD004731.pub3]